MANCHESTER 1824	BSRBRR		nt of Special Interest (ESI) IALIGNANCY
BSRBR The British Society for	Study ID: HRN: Patient Initials:		Gender: Date of Birth: NHS Number:
Rheumatology Biologics Registers Rheumatoid Arthritis	Event Date:	-	biosimilar at time of event: Batch Number:
Event Details			
Details of Malignancy (including diagnosis, location & cell type if available)			
Date of diagnosis:// (Please provide any histopathology/radiology reports)			
Did the patient have: YES NO DON'T KNOW Surgery YES NO DON'T KNOW DON'T KNOW Radiotherapy YES NO DON'T KNOW DON'T KNOW Chemotherapy YES NO DON'T KNOW DON'T KNOW Other treatment: YES NO DON'T KNOW DON'T KNOW			
Was the neoplasm: Benign Malignant Carcinoma in A Metastasis	│ YES │ │ YES │ Situ │ YES │ │ YES │	NO NO NO NO	DON'T KNOW DON'T KNOW DON'T KNOW DON'T KNOW
Did the malignancy have associated metastases? YES NO DON'T KNOW			
Please provide name & hospital of doctor treating the malignancy if available:			
Do you believe there is a possibility that this adverse event was related to the biologic/biosimilar drug used to treat RA? Yes No Unknown If Yes please confirm which drug:			
Form completed By: On://_		utherford H	o: BSRBR-RA. The University of Manchester, louse, 40 Pencroft Way, Manchester Science Park 5 6SZ. You can also fax these to: 0161 2751640